Executive Summary
This week's digest highlights: Preliminary evidence; confirm full-text methods and endpoints before changing practice. When using MAPK-pathway inhibitors in CNS tumors, monitor for intratumoral and intracranial hemorrhage, especially when combining with stereotactic radiosurgery. Consider cervical erector spinae plane block over superficial cervical plexus block for ACDF to improve early recovery quality and...
Owen briefs you on what matters in this week's digest.
Think chief-resident chalk talk: what matters, what changes practice, and where to spend your reading time.
Tumor / Skull Base
Intratumoral and intracranial hemorrhage associated with MAPK-pathway targeted therapy: a systematic review and mechanistic synthesis.
Research • Tumor / Skull Base • Journal of neuro-oncology • 2026-07-15
When using MAPK-pathway inhibitors in CNS tumors, monitor for intratumoral and intracranial hemorrhage, especially when combining with stereotactic radiosurgery.
Study snapshot
Design
Systematic review
Population
Patients with CNS tumors (pediatric and adult) treated with MAPK-pathway targeted therapy
Intervention
MAPK-pathway targeted therapy (BRAF inhibitors, MEK inhibitors, combinations, type II RAF inhibitors)
Comparator
None (single-arm studies and case series)
Primary outcome
Incidence of intratumoral and intracranial hemorrhage
Why it matters
Intratumoral and intracranial hemorrhage have been reported with MAPK-pathway inhibitors, but incidence and risk factors were poorly characterized. This systematic review found that hemorrhage is infrequent but reproducible across agents, with an odds ratio of 3.16 for ICH when BRAF inhibitors are combined with stereotactic radiosurgery. Clinicians should counsel patients about this risk and consider heightened surveillance, especially when combining with radiosurgery.
Practice change
May support increased vigilance for CNS hemorrhage in patients on MAPK inhibitors, particularly when combined with radiosurgery.
More context
Key details
- Systematic review of 10 data sources including clinical trials, FDA labels, and case reports.
- Hemorrhage risk appears across multiple agents (dabrafenib, trametinib, tovorafenib, selumetinib).
- In BREAK-MB, intracranial hemorrhage occurred in 6% of dabrafenib-treated melanoma brain metastasis patients.
- In COMBI-MB, fatal intracranial tumor hemorrhage occurred in 0.8% of patients on dabrafenib + trametinib.
- Tovorafenib FDA label reports 9% intratumoral hemorrhage in pediatric LGG.
- Mechanism may involve rapid tumor necrosis, vascular destabilization, and antiangiogenic effects.
- No prospective study designed specifically to assess CNS hemorrhage as primary endpoint.
High-yield
See source article for primary outcome data.
Clinical context
MAPK-pathway inhibitors are increasingly used in CNS tumors, but hemorrhage risk has been a concern based on case reports and trial safety data. This review systematically aggregates available evidence.
Limitations
Heterogeneous reporting and lack of standardized CNS bleeding definitions across studies.No meta-analysis performed due to heterogeneity; narrative synthesis only.
Methodological critique
Heterogeneous study designs and lack of standardized hemorrhage definitions preclude meta-analysis.
Teaching pearl
When starting a MAPK inhibitor in a patient with a brain tumor, obtain a baseline MRI and maintain a low threshold for repeat imaging if new neurological symptoms develop, as intratumoral hemorrhage can occur even after treatment discontinuation.
Funding and COI
Not stated
Spine
Comparative efficacy of cervical erector spinae plane block and superficial cervical plexus block for postoperative analgesia in anterior cervical discectomy and fusion: A prospective randomized study.
Research • Spine • Medicine • 2026-07-17
Consider cervical erector spinae plane block over superficial cervical plexus block for ACDF to improve early recovery quality and reduce opioid consumption, but recognize that bilateral coverage and higher volume may contribute to the benefit.
Study snapshot
Design
Prospective, randomized study
Population
ASA I-II patients aged 18-65 undergoing single-level ACDF (C5-C6 or C6-C7)
Intervention
Cervical erector spinae plane block (cESPB)
Comparator
Superficial cervical plexus block (sCPB)
Primary outcome
Quality of Recovery-15 (QoR-15) and Visual Analog Scale (VAS) scores
Why it matters
Both cervical erector spinae plane block (cESPB) and superficial cervical plexus block (sCPB) are used for analgesia after ACDF, but comparative data were limited. This RCT found that cESPB was associated with higher Quality of Recovery-15 scores and lower PCA consumption compared to sCPB. Clinicians could consider cESPB as an alternative to sCPB for postoperative analgesia in ACDF, though differences in block laterality and volume may confound results.
Practice change
May support using cESPB over sCPB for ACDF to improve recovery quality and reduce opioid consumption, though results should be interpreted cautiously due to confounding factors.
More context
Key details
- Prospective, randomized study in ASA I-II patients undergoing single-level ACDF (C5-C6 or C6-C7).
- cESPB group received bilateral block; sCPB group received unilateral block on the side of surgical approach.
- Total intraoperative propofol and remifentanil requirements were similar between groups.
- Intraoperative remifentanil consumption was higher in sCPB group at specific time points (T2, T3, T4).
- PCA infusion volumes were significantly lower in cESPB group at 6, 12, and 24 hours postoperatively.
- No significant differences in VAS scores, PONV, or shoulder/neck myofascial pain.
- Authors caution that differences in laterality and local anesthetic volume may confound results.
High-yield
See source article for primary outcome data.
Clinical context
Postoperative pain after ACDF can be significant and opioid-sparing regional analgesia is desirable. Both cESPB and sCPB have been used, but comparative efficacy was unclear.
Limitations
Small sample size (n=20 per group) limits generalizability.Differences in block laterality (bilateral vs unilateral) and total local anesthetic volume confound comparison of block techniques.
Methodological critique
Unilateral sCPB vs bilateral cESPB confounds technique comparison with laterality and volume differences.
Teaching pearl
When performing cervical ESP blocks for ACDF, remember that the block covers both superficial and deep structures; the higher QoR-15 scores suggest better overall recovery quality, not just pain scores.
Funding and COI
Not stated
Functional
Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.
Research • Functional • Epilepsia • 2026-03-28
For patients with drug-resistant focal epilepsy who have failed VNS and are not candidates for resection, ANT-DBS offers a significant reduction in severe seizure frequency.
Study snapshot
Design
Randomized controlled trial
Population
Patients with drug-resistant focal epilepsy, ineligible for or failed resective surgery, and failed VNS
Intervention
Bilateral anterior nucleus of thalamus deep brain stimulation (ANT-DBS)
Comparator
Best medical treatment (BMT)
Primary outcome
≥50% reduction in frequency of severe seizures (types B, C, D) at 1 year
Why it matters
Before this study, ANT-DBS showed promise for drug-resistant epilepsy but lacked confirmatory randomized data in patients who failed VNS. This randomized trial demonstrates that ANT-DBS significantly reduces severe seizure frequency compared to best medical treatment alone. Clinicians should consider ANT-DBS for patients with drug-resistant focal epilepsy who are not candidates for resection and have failed VNS.
Practice change
May support offering ANT-DBS to patients with drug-resistant focal epilepsy who have failed VNS and are not candidates for resection.
More context
Key details
- Randomized, controlled trial at 14 French DBS centers (2014-2019).
- 61 patients with drug-resistant focal epilepsy, ineligible for or failed surgery, and failed VNS.
High-yield
ANT-DBS achieved ≥50% reduction in severe seizures in significantly more patients than best medical treatment at 1 year (p<.05).
Clinical context
Approximately one-third of epilepsy patients are drug-resistant, and for those not candidates for resection, neuromodulation options like VNS and DBS are considered.
Limitations
Open-label design due to inability to sham-stimulate, introducing potential bias.Sample size modest (n=61) and no adjustment for multiple secondary endpoints.
Methodological critique
Open-label design without sham control may introduce bias in outcome assessment.
Teaching pearl
When counseling patients about ANT-DBS, emphasize that the primary outcome is reduction in severe seizures (types B-D), not total seizure freedom, and that response may improve over time.
Funding and COI
Not stated
General Neurosurgery
Long-term outcomes following primary resection of intraosseous meningiomas with concurrent cranioplasty: a population-based Swedish multicentre study.
Research • General Neurosurgery • Acta neurochirurgica • 2026-07-18
Preliminary evidence; confirm full-text methods and endpoints before changing practice.
Study snapshot
Design
Multicenter retrospective cohort study
Population
Patients who underwent primary resection of intraosseous meningioma with concurrent cranioplasty at four Swedish centers (2008-2022)
Intervention
Primary resection of intraosseous meningioma with concurrent cranioplasty
Comparator
None (single-arm cohort)
Primary outcome
Rates of surgical complications requiring reoperation and tumor recurrence (including growth of residual tumor)
Why it matters
Before this study, outcomes after resection of intraosseous meningiomas with cranioplasty were poorly characterized. This multicenter cohort provides long-term data showing high rates of surgical complications (16%) and tumor recurrence (31%). Clinicians should counsel patients about these risks and focus on biological tumor factors rather than implant material when planning surgery.
Practice change
Confirms current practice that implant material choice does not significantly impact outcomes; biological tumor factors are more important.
More context
Key details
- Population-based multicenter cohort from four Swedish neurosurgical departments (2008-2022).
- 119 patients who underwent primary resection of intraosseous meningioma with concurrent cranioplasty.
- Retrospective data collection from medical records.
- Choice of implant material differed across centers but did not influence complication rates.
- Markers of biological aggressiveness were associated with increased risk of complications and recurrence.
- Cox regression used to analyze predictors of complications and recurrence.
High-yield
31% of patients developed tumor recurrence and 16% required reoperation for complications after primary resection of intraosseous meningioma with concurrent cranioplasty.
Clinical context
Intraosseous meningiomas are rare, and studies on surgical outcomes with cranioplasty are limited. Previous literature is mostly small case series.
Limitations
Retrospective design with potential for incomplete data and selection bias.No central pathology review, and implant material choice was not randomized.
Methodological critique
Retrospective design limits causal inference and may miss unreported complications.
Teaching pearl
When planning cranioplasty for intraosseous meningioma, remember that implant material choice did not affect complication rates; focus on achieving gross total resection and assessing biological aggressiveness.
Funding and COI
Not stated
Basic Science
iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engager.
Research • Basic Science • Neuro-oncology • 2026-07-11
Preclinical evidence; no immediate practice change pending clinical validation.
Why it matters
Mechanistic work may identify targets that later translate into neurosurgical oncology or neuroregeneration therapies.
High-yield
Basic science (preclinical); mechanistic endpoints in methods; not applicable (preclinical).
Trials to Know
AI Prediction of Sarcopenia Risk in Neurocritical ICU Patients
Trial • Trials to Know • ClinicalTrials.gov • 2026-07-19
Why it matters
This prospective observational study uses AI to predict sarcopenia risk in neurocritical patients with conditions like intracerebral hemorrhage, subarachnoid hemorrhage, and brain tumors. Sarcopenia is a known predictor of poor outcomes in neurosurgical patients, and early identification could guide nutritional and rehabilitation interventions. The trial addresses the gap in objective risk stratification tools for muscle wasting in the neuro-ICU.
XR-Assisted CT-Guided Localization in EC-IC Bypass Surgery
Trial • Trials to Know • ClinicalTrials.gov • 2026-07-19
Why it matters
This trial evaluates the use of an extended reality (XR) platform for CT-guided localization during EC-IC bypass surgery, aiming to improve surgical precision in patients with chronic cerebral ischemia or moyamoya disease. If successful, XR-assisted navigation could enhance graft placement and reduce complications, addressing a key technical challenge in revascularization surgery.
Pivotal Study of Silk Vista Baby Flow Diverters in Unruptured Intracranial Aneurysms (PIONEER)
Trial • Trials to Know • ClinicalTrials.gov • 2026-07-19
Why it matters
This trial evaluates the Silk Vista Baby (SVB) flow diverter for treating unruptured intracranial aneurysms, a common condition in neurosurgical practice. It addresses the need for evidence on newer generation flow diverters designed for smaller vessels, potentially expanding endovascular treatment options. Results could influence device selection and procedural outcomes for neurosurgeons managing these aneurysms.
From the Preprint Wire
Hemispheric Asymmetry Features and Interpretable Machine Learning for Focal Cortical Dysplasia Classification in Drug-Resistant Epilepsy
Preprint • From the Preprint Wire • medrxiv • 2026-07-06
Why it matters
This preprint (NOT peer-reviewed) presents a machine learning approach to detect focal cortical dysplasia (FCD) on structural MRI, a common cause of drug-resistant epilepsy that is often missed by radiologists. For neurosurgeons, improved FCD detection could enhance surgical candidate selection and planning, but the unreviewed results require cautious interpretation before clinical application.
More context
Key details
- 50 subjects (25 FCD, 25 controls) from a public structural MRI cohort were analyzed.
- Hemispheric asymmetry features were computed across 48 cortical regions per hemisphere (96 total features).
- L1-regularized logistic regression achieved 78% accuracy (p=0.02) under leave-one-out cross-validation.
- The model selected 21 features, with largest contributions from inferior/middle frontal gyri, temporal pole, and superior temporal gyrus.
- Tree-based ensembles performed at or below chance, highlighting the importance of regularization in high-dimensional settings.
Automated Multisource Electronic Frailty Index in Acute Ischemic Stroke: Development and Clinical Utility
Preprint • From the Preprint Wire • medrxiv • 2026-07-06
Why it matters
This preprint (not peer-reviewed) presents an automated electronic frailty index (eFI) derived from multisource EMR data that predicts outcomes in acute ischemic stroke patients. For neurosurgeons, frailty assessment is often overlooked but may improve risk stratification and discharge planning; however, as unreviewed work, its generalizability and real-world applicability remain uncertain.
More context
Key details
- Developed a fully automated pipeline to derive eFI from 3-year EMR lookback, including AI-augmented extraction from free-text documentation.
- Among 492 AIS cases, each 0.1-unit eFI increase was associated with 47% higher hazard of post-discharge mortality (adjusted HR 1.47) and 91% higher odds of 30-day readmission (adjusted OR 1.91).
- Frail patients had greater premorbid disability, higher stroke severity, longer hospitalization, and worse discharge outcomes.
Policy & Systems / Advocacy
CNS Position Statement on Insurance Coverage for Interbody Biomechanical Devices (CPT 22853) in Cervical Spine Arthrodesis
News • Policy & Systems / Advocacy • CNS • 2026-05-11
Why it matters
This position statement addresses insurance coverage for interbody biomechanical devices used in cervical spine arthrodesis, which directly impacts surgical practice and patient access. Neurosurgeons must be aware of payer policies that may restrict use of these devices, affecting surgical planning and reimbursement.
More context
Key details
- The CNS has issued a position statement on insurance coverage for CPT 22853 (interbody biomechanical devices) in cervical spine arthrodesis.
- The statement likely advocates for appropriate coverage based on clinical evidence and surgical necessity.
- Insurance denials for these devices can limit surgical options and increase costs for patients and hospitals.